Lambert-Eaton Myasthenic Syndrome Recurrence Induced by Pembrolizumab in a Patient with Non-small-cell Lung Cancer

A 73-year-old woman in complete remission from localized small-cell lung cancer associated with Lambert-Eaton myasthenic syndrome (LEMS) 22 years earlier was referred to our hospital and diagnosed with non-small-cell lung cancer. After three courses of pembrolizumab, an immune checkpoint inhibitor,...

Descripción completa

Detalles Bibliográficos
Autores principales: Takigawa, Yuki, Watanabe, Hiromi, Omote, Yoshio, Kurihara, Sunao, Inoue, Tomoyoshi, Fujiwara, Miho, Mitsumune, Sho, Onishi, Kiriko, Kudo, Kenichiro, Sato, Akiko, Sato, Ken, Fujiwara, Keiichi, Shibayama, Takuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10125817/
https://www.ncbi.nlm.nih.gov/pubmed/36047125
http://dx.doi.org/10.2169/internalmedicine.0072-22
_version_ 1785030106008256512
author Takigawa, Yuki
Watanabe, Hiromi
Omote, Yoshio
Kurihara, Sunao
Inoue, Tomoyoshi
Fujiwara, Miho
Mitsumune, Sho
Onishi, Kiriko
Kudo, Kenichiro
Sato, Akiko
Sato, Ken
Fujiwara, Keiichi
Shibayama, Takuo
author_facet Takigawa, Yuki
Watanabe, Hiromi
Omote, Yoshio
Kurihara, Sunao
Inoue, Tomoyoshi
Fujiwara, Miho
Mitsumune, Sho
Onishi, Kiriko
Kudo, Kenichiro
Sato, Akiko
Sato, Ken
Fujiwara, Keiichi
Shibayama, Takuo
author_sort Takigawa, Yuki
collection PubMed
description A 73-year-old woman in complete remission from localized small-cell lung cancer associated with Lambert-Eaton myasthenic syndrome (LEMS) 22 years earlier was referred to our hospital and diagnosed with non-small-cell lung cancer. After three courses of pembrolizumab, an immune checkpoint inhibitor, the patient complained of muscle weakness, fatigue, ptosis, and dysarthria. The anti-voltage-gated calcium channel antibody level was elevated, and waxing was observed on a high-frequency repetitive stimulation test using an electromyogram. We diagnosed her with recurrence of LEMS as an immune-related adverse event (irAE) induced by pembrolizumab. After intravenous immunoglobulin therapy, the patient's symptoms improved, and she was discharged.
format Online
Article
Text
id pubmed-10125817
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-101258172023-04-26 Lambert-Eaton Myasthenic Syndrome Recurrence Induced by Pembrolizumab in a Patient with Non-small-cell Lung Cancer Takigawa, Yuki Watanabe, Hiromi Omote, Yoshio Kurihara, Sunao Inoue, Tomoyoshi Fujiwara, Miho Mitsumune, Sho Onishi, Kiriko Kudo, Kenichiro Sato, Akiko Sato, Ken Fujiwara, Keiichi Shibayama, Takuo Intern Med Case Report A 73-year-old woman in complete remission from localized small-cell lung cancer associated with Lambert-Eaton myasthenic syndrome (LEMS) 22 years earlier was referred to our hospital and diagnosed with non-small-cell lung cancer. After three courses of pembrolizumab, an immune checkpoint inhibitor, the patient complained of muscle weakness, fatigue, ptosis, and dysarthria. The anti-voltage-gated calcium channel antibody level was elevated, and waxing was observed on a high-frequency repetitive stimulation test using an electromyogram. We diagnosed her with recurrence of LEMS as an immune-related adverse event (irAE) induced by pembrolizumab. After intravenous immunoglobulin therapy, the patient's symptoms improved, and she was discharged. The Japanese Society of Internal Medicine 2022-08-30 2023-04-01 /pmc/articles/PMC10125817/ /pubmed/36047125 http://dx.doi.org/10.2169/internalmedicine.0072-22 Text en Copyright © 2023 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Takigawa, Yuki
Watanabe, Hiromi
Omote, Yoshio
Kurihara, Sunao
Inoue, Tomoyoshi
Fujiwara, Miho
Mitsumune, Sho
Onishi, Kiriko
Kudo, Kenichiro
Sato, Akiko
Sato, Ken
Fujiwara, Keiichi
Shibayama, Takuo
Lambert-Eaton Myasthenic Syndrome Recurrence Induced by Pembrolizumab in a Patient with Non-small-cell Lung Cancer
title Lambert-Eaton Myasthenic Syndrome Recurrence Induced by Pembrolizumab in a Patient with Non-small-cell Lung Cancer
title_full Lambert-Eaton Myasthenic Syndrome Recurrence Induced by Pembrolizumab in a Patient with Non-small-cell Lung Cancer
title_fullStr Lambert-Eaton Myasthenic Syndrome Recurrence Induced by Pembrolizumab in a Patient with Non-small-cell Lung Cancer
title_full_unstemmed Lambert-Eaton Myasthenic Syndrome Recurrence Induced by Pembrolizumab in a Patient with Non-small-cell Lung Cancer
title_short Lambert-Eaton Myasthenic Syndrome Recurrence Induced by Pembrolizumab in a Patient with Non-small-cell Lung Cancer
title_sort lambert-eaton myasthenic syndrome recurrence induced by pembrolizumab in a patient with non-small-cell lung cancer
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10125817/
https://www.ncbi.nlm.nih.gov/pubmed/36047125
http://dx.doi.org/10.2169/internalmedicine.0072-22
work_keys_str_mv AT takigawayuki lamberteatonmyasthenicsyndromerecurrenceinducedbypembrolizumabinapatientwithnonsmallcelllungcancer
AT watanabehiromi lamberteatonmyasthenicsyndromerecurrenceinducedbypembrolizumabinapatientwithnonsmallcelllungcancer
AT omoteyoshio lamberteatonmyasthenicsyndromerecurrenceinducedbypembrolizumabinapatientwithnonsmallcelllungcancer
AT kuriharasunao lamberteatonmyasthenicsyndromerecurrenceinducedbypembrolizumabinapatientwithnonsmallcelllungcancer
AT inouetomoyoshi lamberteatonmyasthenicsyndromerecurrenceinducedbypembrolizumabinapatientwithnonsmallcelllungcancer
AT fujiwaramiho lamberteatonmyasthenicsyndromerecurrenceinducedbypembrolizumabinapatientwithnonsmallcelllungcancer
AT mitsumunesho lamberteatonmyasthenicsyndromerecurrenceinducedbypembrolizumabinapatientwithnonsmallcelllungcancer
AT onishikiriko lamberteatonmyasthenicsyndromerecurrenceinducedbypembrolizumabinapatientwithnonsmallcelllungcancer
AT kudokenichiro lamberteatonmyasthenicsyndromerecurrenceinducedbypembrolizumabinapatientwithnonsmallcelllungcancer
AT satoakiko lamberteatonmyasthenicsyndromerecurrenceinducedbypembrolizumabinapatientwithnonsmallcelllungcancer
AT satoken lamberteatonmyasthenicsyndromerecurrenceinducedbypembrolizumabinapatientwithnonsmallcelllungcancer
AT fujiwarakeiichi lamberteatonmyasthenicsyndromerecurrenceinducedbypembrolizumabinapatientwithnonsmallcelllungcancer
AT shibayamatakuo lamberteatonmyasthenicsyndromerecurrenceinducedbypembrolizumabinapatientwithnonsmallcelllungcancer

Ejemplares similares